Background & aims Normal/mildly elevated ALT (< 2× ULN) CHB patients are potentially at
risk of progression to cirrhosis and/or hepatocellular carcinoma (HCC). We aimed to assess …

Background & Aims Recent studies reveal that the rate of normal on-treatment alanine
aminotransferase (ALT) appears different for different nucleos (t) ide analogues (NAs); yet its …

For chronic hepatitis B (CHB), alanine aminotransferase (ALT)≥ 2× upper limit of normal
(ULN) is often used as a major criteria to initiate treatment in absence of cirrhosis, though …

Background There are inadequate data and no histological evidence regarding the effects of
antiviral treatment for hepatitis B e-antigen (HBeAg)-negative chronic hepatitis B (CHB) …

Methods Medline, Embase, and Cochrane Library were searched up to January 10 th 2020,
to identify studies of these patients with liver biopsy. The double arcsine method was used …

Background Sustained abnormal serum alanine aminotransferase (ALT) levels can increase
the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. Aim This …

Summary Background Chronic hepatitis B (CHB) may lead to cirrhosis, hepatocellular
carcinoma and premature death. Elevated alanine transaminase (ALT) levels≥ the upper …

Background & Aims The level of alanine aminotransferase (ALT) is a marker of hepatitis B
severity and response to treatment. However, measurements of ALT level may be of limited …

Background It remains unknown whether antiviral treatment for HBeAg‐negative chronic
hepatitis B (CHB) patients having high viral loads without significant elevation of alanine …

Background and aims A proportion of chronic hepatitis B virus (HBV) infection patients with
normal alanine aminotransferase (ALT) should start antiviral therapy based on liver biopsy …